intrinsic-factor and Precursor-Cell-Lymphoblastic-Leukemia-Lymphoma

L-Asparaginase (ASNase) is a biopharmaceutical used as an essential drug in the treatment of acute lymphoblastic leukemia (ALL). Yet, some cases of ALL are naturally resistant to ASNase treatment, which results in poor prognosis. The REH ALL cell line, used as a model for studying the most common subtype of ALL, is considered resistant to treatment with ASNase. Cathepsin B (CTSB) is one of the proteases involved in the regulation of in vivo ASNase serum half-life and it has also been associated with the progression and resistance to treatment of several solid tumors. Previous works have shown that, in vitro, ASNase is degraded when incubated with REH cell lysate, which is prevented by a specific CTSB inhibitor, suggesting a function of this protease in the ASNase resistance of REH cells. In this work, we utilized a combination of CRISPR/Cas9 gene targeting and enzymatic measurements to investigate the relevance of CTSB on ASNase treatment resistance in the ALL model cell line. We found that deletion of CTSB in REH ALL cells did not confer ASNase treatment sensitivity, thus suggesting that intrinsic expression of

Topics: Antineoplastic Agents; Asparaginase; Cathepsin B; Cell Line; Humans; Intrinsic Factor; Precursor Cell Lymphoblastic Leukemia-Lymphoma

Topics: Child, Preschool; Female; Humans; Intrinsic Factor; Mutation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Vitamin B 12 Deficiency